secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rafael Holdings, Inc. (RFL)
CIK:        0001713863
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001213900-24-107632
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rafael Holdings Q1 FY2025 net loss $9.0M; Cyclo merger on track
---------------------------------------------------------------

- Net loss attributable to Rafael Holdings of $9.0M ($0.37 per share) vs $3.6M loss a year ago.
- Cash, cash equivalents and marketable securities of $54.3M as of October 31, 2024.
- Pending merger with Cyclo Therapeutics (CYTH) expected to close in Q1 2025 after shareholder vote.
- Cyclo Therapeutics' Phase 3 study for Trappsol Cyclo fully enrolled; interim results mid-2025.
- R&D expenses $1.3M (up from $0.5M) on consolidation of Cornerstone and Day Three.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/0001213900-24-107632-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/ea0224341-8k_rafael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-107632

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer